What blood test should one get when taking Carbamazepine (Tegretol)?

What blood test should one get when taking Carbamazepine (Tegretol)?

• A. Liver function tests
• B. Electrolyte panel
• C. CBC to monitor for agranulocytosis and aplastic anemia
• D. Creatinine levels

Answer: (C)

When a patient is taking Carbamazepine (Tegretol), it is crucial to monitor for potential hematological side effects, particularly agranulocytosis and aplastic anemia. Carbamazepine is known to affect bone marrow function, which can lead to decreased levels of blood cells. These conditions can result in serious complications, including an increased risk of infections due to low white blood cell counts and increased risk of bleeding due to low platelet levels. A complete blood count (CBC) is the necessary test to monitor these parameters effectively. Regular CBCs can help detect these hematological issues early, allowing for timely intervention if abnormalities are found. Therefore, the rationale for this choice lies in the need for vigilant monitoring of blood cell levels in patients undergoing treatment with Carbamazepine. Other tests, while useful in different contexts, do not specifically address the critical concerns associated with Carbamazepine therapy. Liver function tests are important for monitoring potential hepatic side effects of various medications, but they are not the primary concern with Carbamazepine. An electrolyte panel may provide insights into metabolic status, but it does not specifically correlate to the hematological risks associated with the drug. Creatinine levels can help monitor renal function, but again, this does

When a patient is taking Carbamazepine (Tegretol), it is crucial to monitor for potential hematological side effects, particularly agranulocytosis and aplastic anemia. Carbamazepine is known to affect bone marrow function, which can lead to decreased levels of blood cells. These conditions can result in serious complications, including an increased risk of infections due to low white blood cell counts and increased risk of bleeding due to low platelet levels.

A complete blood count (CBC) is the necessary test to monitor these parameters effectively. Regular CBCs can help detect these hematological issues early, allowing for timely intervention if abnormalities are found. Therefore, the rationale for this choice lies in the need for vigilant monitoring of blood cell levels in patients undergoing treatment with Carbamazepine.

Other tests, while useful in different contexts, do not specifically address the critical concerns associated with Carbamazepine therapy. Liver function tests are important for monitoring potential hepatic side effects of various medications, but they are not the primary concern with Carbamazepine. An electrolyte panel may provide insights into metabolic status, but it does not specifically correlate to the hematological risks associated with the drug. Creatinine levels can help monitor renal function, but again, this does